Human CD25 (C-Fc) on SDS-PAGE under reducing condition (P+) and non-reducing condition (P-). The gel was stained for 1 hour with BlinkBlue (catalog 700102). The purity of this protein appears to be greater than 95%.
Cat #
Size
Price
Quantity
812901
25 ug
$145
812902
100 ug
$295
Product Details
Application
ELISA, BLI
Format
Liquid, Purified
Expression Host
CHO
Target Name
IL2RA, CD25, p55
Species
Human
Sources
Recombinant Human CD25 (Glu22-Cys213) with C-terminus Fc-tag is expressed in CHO cell.
accession number
P01589
Molecular Weight
The protein has a predicted molecular weight of 48.0 kDa. Under DTT-reducing conditions, it migrates at approximately 65 kDa on SDS-PAGE.
Affinity Tag
C-Fc
Purity
>95% based on SDS-PAGE under reducing condition
Formulation
1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin level
Not tested
Protein Concentration
25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and Handling
Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.
Background Information
CD25 (IL2RA), a type I transmembrane glycoprotein, is expressed on activated T cells, regulatory T cells, and dendritic cells. It binds IL-2 with low affinity on its own, but upon associating with the IL-2 receptor beta (CD122) and common gamma chain (CD132), it forms a high-affinity complex that triggers intracellular signaling pathways like MAPK and JAK/STAT. CD25 is involved in immune regulation and plays a role in autoimmune diseases, including type 1 diabetes. Soluble CD25 (sIL-2Ralpha) is released during immune responses and is a marker for tumor burden in hematological malignancies, including leukemias and lymphomas, as well as some solid tumors like melanoma and carcinomas. The presence of sIL-2Ralpha in circulation reflects tumor activity and is associated with immune modulation in cancer progression.